Abstract
CD4+ CD25+ regulatory T cells (Tregs) have far-reaching immunotherapeutic applications, the realization of which will require a greater understanding of the factors influencing their function and phenotype during ex vivo manipulation. In murine models, IL-2 plays an important role in both the maintenance of a functional Treg population in vivo and the activation of suppression in vitro. We have found that IL-2 maintains optimal function of human CD4+ CD25+ Tregs in vitro and increases expression of both forkhead box protein 3, human nomenclature (FOXP3) and the distinctive markers CD25, cytotoxic T lymphocyte antigen-4 (CTLA-4) and glucocorticoid-induced tumor necrosis factor receptor superfamily member number 18 (GITR). Although IL-2 reduced spontaneous apoptosis of Tregs, this property alone could not account for the optimal maintenance of the regulatory phenotype. The inhibition of phosphatidylinositol 3-kinase (PI3K) signaling by LY294002, a chemical inhibitor of PI3K, abolished the maintenance of maximal suppressive potency by IL-2, yet had no effect on the up-regulation of FOXP3, CD25, CTLA-4 and GITR. Other common gamma chain (gammac) cytokines-IL-4, IL-7 and IL-15-had similar properties, although IL-4 showed a unique lack of effect on the expression of FOXP3 or Treg markers despite maintaining maximal regulatory function. Taken together, our data suggest a model in which the gammac cytokines IL-2, IL-4, IL-7 and IL-15 maintain the optimal regulatory function of human CD4+ CD25+ T cells in a PI3K-dependent manner, offering new insight into the effective manipulation of Tregs ex vivo.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigens, CD / metabolism
-
Antigens, Differentiation / metabolism
-
Apoptosis / drug effects
-
Blotting, Western
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology
-
CD4-Positive T-Lymphocytes / metabolism
-
CTLA-4 Antigen
-
Cell Proliferation / drug effects
-
Chromones / pharmacology
-
Coculture Techniques
-
Cyclosporine / pharmacology
-
Flow Cytometry
-
Forkhead Transcription Factors / metabolism
-
Glucocorticoid-Induced TNFR-Related Protein
-
HLA-DR Antigens / metabolism
-
Humans
-
Immune Tolerance / drug effects
-
Immune Tolerance / immunology
-
Interleukin-15 / pharmacology*
-
Interleukin-2 / pharmacology*
-
Interleukin-2 Receptor alpha Subunit / analysis*
-
Interleukin-2 Receptor alpha Subunit / metabolism
-
Interleukin-4 / pharmacology*
-
Interleukin-6 / pharmacology
-
Interleukin-7 / pharmacology*
-
Morpholines / pharmacology
-
Phosphoinositide-3 Kinase Inhibitors
-
Phosphorylation / drug effects
-
Proto-Oncogene Proteins c-akt / metabolism
-
Receptors, Antigen, T-Cell / antagonists & inhibitors
-
Receptors, Nerve Growth Factor / metabolism
-
Receptors, Tumor Necrosis Factor / metabolism
-
T-Lymphocytes, Regulatory / drug effects
-
T-Lymphocytes, Regulatory / metabolism*
-
T-Lymphocytes, Regulatory / physiology
Substances
-
Antigens, CD
-
Antigens, Differentiation
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Chromones
-
FOXP3 protein, human
-
Forkhead Transcription Factors
-
Glucocorticoid-Induced TNFR-Related Protein
-
HLA-DR Antigens
-
Interleukin-15
-
Interleukin-2
-
Interleukin-2 Receptor alpha Subunit
-
Interleukin-6
-
Interleukin-7
-
Morpholines
-
Phosphoinositide-3 Kinase Inhibitors
-
Receptors, Antigen, T-Cell
-
Receptors, Nerve Growth Factor
-
Receptors, Tumor Necrosis Factor
-
TNFRSF18 protein, human
-
Interleukin-4
-
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
-
Cyclosporine
-
Proto-Oncogene Proteins c-akt